Anti-amyloid beta antibodies and methods of using the same
The present inventive concept is related to antibodies, such as recombinant humanized and monoclonal antibodies, methods of making antibodies, and methods of using antibodies, such as antibodies directed toward and capable of specifically binding to and clearing amyloid-beta (Aβ) plaques in the brain that are suitable for use in the treatment of disorders such as Alzheimer's Disease (AD).
1. An anti-human Aβ pE3 antibody which comprises (i) a variable heavy chain (vH) comprising 3 CDRs; and (ii) a variable light chain (vL) comprising 3 CDRs, wherein:
(SEQ ID NO: 1)
vH CDR1 is GFSLSTSGMGVS;
(SEQ ID NO: 2)
vH CDR2 is HIYWDDDKRYNPYMKR;
(SEQ ID NO: 3)
vH CDR3 is RADDYDVGFAY;
(SEQ ID NO: 4)
vL CDR1 is LASQTIGTWLA;
(SEQ ID NO: 5)
vL CDR2 is AATSLAD;
and
(SEQ ID NO: 6)
vL CDR3 is QQLYSSPFT.
2. The anti-human Aβ pE3 antibody of claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO:7 and a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO:8.
3. An anti-human Aβ pE3 antibody which comprises two heavy chains, each heavy chain comprising the amino acid sequence set forth as SEQ ID NO:9, and two light chains, each light chain comprising the amino acid sequence set forth as SEQ ID NO:10.
4. An anti-human Aβ pE3 antibody, wherein the antibody comprises two heavy chains, each heavy chain comprising the amino acid sequence set forth as SEQ ID NO: 37 and two light chains, each light chain comprising the amino acid sequence set forth as SEQ ID NO: 10.
5. The anti-human Aβ pE3 antibody of claim 1 , wherein the antibody comprises a human IgG1 constant region.
6. The anti-human Aβ pE3 antibody of claim 5 , wherein the antibody comprises a kappa light chain constant region.